NCT07009860Phase 2Active not recruiting

RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Study sponsor: Altimmune, Inc. · ALT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09-30Estimated
Enrollment · participants121Actual
Source updated2026-08-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24. After: Measure: Relative (%) reduction in liver stiffness by VCTE compared to baseline.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 100 participants (planned). After: 121 participants (actual).

Primary completion date changed

Before: 31 Mar 2027. After: 30 Sep 2027.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview